Evidence map›Paper›PMID 28802251›Full record

ArticleMolecular cancer therapeutics2017

MicroRNA-720 Regulates E-cadherin-αE-catenin Complex and Promotes Renal Cell Carcinoma.

Nadeem S Bhat, Melissa Colden, Altaf A Dar, Sharanjot Saini, Prerna Arora, Varahram Shahryari, Soichiro Yamamura, Yuichiro Tanaka, Taku Kato, Shahana Majid and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. A Review of Recent Research on the Role of MicroRNAs in Renal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2021
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nadeem S BhatDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Melissa ColdenDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Altaf A DarResearch Institute, California Pacific Medical Center, San Francisco, California.
Sharanjot SainiDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Prerna AroraDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Varahram ShahryariDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Soichiro YamamuraDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Yuichiro TanakaDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Taku KatoDepartment of Urology, VA Medical Center and UCSF, San Francisco, California.
Shahana MajidDepartment of Urology, VA Medical Center and UCSF, San Francisco, California. Shahana.Majid@ucsf.edu rdahiya@ucsf.edu.
Rajvir DahiyaDepartment of Urology, VA Medical Center and UCSF, San Francisco, California. Shahana.Majid@ucsf.edu rdahiya@ucsf.edu.
San Francisco VA Medical Center · USCalifornia Pacific Medical Center · US

Funding

Molecular biomarkers for kidney cancer prognosis using non-coding RNAsR01CA199694 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI TANAKA, YUICHIRO · 2016 to 2020
$1.7M
Regulation of c-Myc/HIF pathway in the management of kidney cancerI01BX001123 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI DAHIYA, RAJVIR · 2012 to 2020
–
Role of genetic biomarkers in clinical assessment of prostate cancerIP1BX001604 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI DAHIYA, RAJVIR, LAU, YUN-FAI CHRIS · 2013 to 2016
–
BLRD VA I01 BX001123BLRD VA IK6 BX004473BLRD VA IP1 BX001604NCI NIH HHS R01 CA199694
6 · The paper itself

Abstract

miRNAs are implicated in regulating cancer progression and metastasis. Here, we show that miR-720 is positively associated with renal cell carcinoma (RCC). Elevated levels of miR-720 were observed in a panel of RCC cell lines and clinical tissues compared with nonmalignant cell line and normal samples. Loss of miR-720 function inhibited proliferation, migration, and invasion and induced apoptosis in RCC cell lines

Indexed as

AnimalsAntigens, CDCadherinsCarcinoma, Renal CellCell Line, TumorHeterograftsHumansKidney NeoplasmsMiceMice, NudeMicroRNAsAntigens, CDCadherinsCDH1 protein, humanMicroRNAsMIRN720 microRNA, human

Identifiers

PMID28802251
PMCPMC5893503
OpenAlexW2744732242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.